Related Experiment Videos
Management of patients with rising prostate-specific antigen after radical prostatectomy
M Laufer1, C R Pound, M A Carducci
1Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-8936, USA.
Urology
|March 4, 2000
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
bioRxiv : the preprint server for biology·2024
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.
Kidney cancer (Clifton, Va.)·2018